BridgeBio Pharma, Inc. Common Stock BBIO

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

• Zacks Investment Research 16 sept

  BioMarin Stops Voxzogo Development for Noonan Syndrome

  BioMarin Pharmaceutical announced it is discontinuing development of Voxzogo for Noonan syndrome due to study feasibility and treatment landscape concerns, though not due to safety or efficacy issues. Despite this setback, Voxzogo generated $472 million in first-half 2026 sales (up 9% YoY) and is on track to achieve blockbuster status with expected 2026 sales of $1.00-$1.05 billion. The drug faces increasing competition from Ascendis Pharma's Yuviwel and BridgeBio's infigratinib, though BioMarin secured a royalty-bearing settlement with Ascendis.

  

• Zacks Investment Research 3 sept

  How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset

  BioMarin settled a patent dispute with Ascendis Pharma over the achondroplasia drug Yuviwel, converting a competitive threat into a royalty stream. Under the agreement, BioMarin will receive 20% royalties on U.S. Yuviwel sales and 18% in the EU, Brazil, and South Korea through May 2030. While this monetizes competition, BioMarin still faces market pressure from Yuviwel and potential future competitors like BridgeBio's infigratinib.

  

• GlobeNewswire Inc. 31 ago

  BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

  BridgeBio Pharma has entered into a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine Attruby and lower drug costs for American patients. The agreement includes expanded state Medicaid access via the GENEROUS Model and maintains the company's ForgingBridges patient assistance program. BridgeBio expects not to be subject to future pricing mandates under this arrangement.

  

• The Motley Fool 14 ago

  BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

  BridgeBio Pharma's stock has surged 29% in three months, driven by strong performance of its FDA-approved heart medication Attruby, which saw sales more than triple year-over-year to $222 million in Q2. With 16 out of 17 analysts recommending a buy and three promising drugs in late-stage development under FDA review, Wall Street believes the stock has further upside potential despite the company remaining unprofitable.

  

• GlobeNewswire Inc. 7 jul

  Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

  The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.